scholarly journals NON-ALCOHOLIC FATTY LIVER DISEASE – AN AYURVEDIC VIEW

2021 ◽  
Vol 9 (11) ◽  
pp. 2797-2801
Author(s):  
Aparna Chandran ◽  
Mahadevan L. ◽  
Nisha M.G ◽  
Arun Pratap
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Developed Countries ◽  
Developing Nations ◽  
Alcoholic Fatty Liver ◽  
Liver Disorders ◽  
The World ◽  
Function Test ◽  
Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease (NAFLD) is a distinct hepatic condition characterized by abnormal fat accumu- lation in liver cells and histologically it resembles alcohol-induced liver damage. The prevalence of NAFLD is up to 30% in developed countries and 10% in developing nations, making NAFLD the most common liver condition in the world. The liver can be compared with Yakrit (Liver) mentioned in Ayurvedic classics as an important Ko- shtanga (organ of the gastrointestinal system). But NAFLD as such could not be correlated to any of the Yakrit Rogas (Liver disorders) mentioned in Ayurvedic classics. Understanding the Nidana (aetiology) and Samprapti (pathogenesis) of the disease, NAFLD can be considered as a Santarpanajanya Vyadhi (disease due to over nour- ishment). Here initially Agnivikruti (deranged digestive fire) occurs which leads to the formation of Ama (Free radicals) which results from the vitiation of Kaphadosha and further results in unequal formation and deposition of Dushta Vasa (triglycerides) in Yakrit. Hence Agnideepana (stimulating digestive fire), Amapachana (antioxidation), Lekhana (scraping), Srotosodhana (clearing of channels of circulation), Kapha Medohara (antihyperlipidemic) and Vataanulomana (normalising the movement of Vata) is aimed primarily in the management of NAFLD Keywords: Non-Alcoholic Fatty Liver Disease, Ultrasonography, Liver Function Test, Santarpanajanya Vyadhi

Prevention effects of black soybean polyphenols on non-alcoholic fatty liver disease in three different model mice

2022 ◽  
Author(s):  
Mio Yamamoto ◽  
Yasukiyo Yoshioka ◽  
Tomoya Kitakaze ◽  
Yoko Yamashita ◽  
Hitoshi Ashida
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Major Health ◽  
Black Soybean ◽  
Food Components ◽  
The World ◽  
Alcoholic Fatty Liver Disease ◽  
Major Health Issue

Non-alcoholic fatty liver disease (NAFLD) and its advanced stage, non-alcoholic steatohepatitis (NASH) are a major health issue throughout the world. Certain food components such as polyphenols are expected to possess...

Non-alcoholic fatty liver disease – discussed under the light of Unani medicine

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Mohd Riyazuddin ◽  
Arisha Shahid
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Dietary Habits ◽  
Primary Source ◽  
Developed Countries ◽  
The Body ◽  
Excessive Alcohol Consumption ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Non-alcoholic Fatty Liver Disease (NAFLD) is one of the diseases that have evolved lately into a major challenge for gastroenterologists. Although, the term NAFLD has not been familiar to the medical world since long, other conditions resembling the presentation of NAFLD have been there since primitive times. It is a reversible condition of the liver, wherein large vacuoles of triglyceride fat accumulates in liver cells via the process of steatosis, despite any evidence of excessive alcohol consumption. In the developed countries NAFLD is reported to be the most common liver disorder, with a worldwide prevalence of 6–35%, in India its prevalence has been increasing gradually. Unani physicians have described liver as one of the principal organs of the body. It is the primary source of natural faculties, where the functions of digestion, concoction, absorption and excretion are performed, normally temperament of liver is hot and moist which can get converted to cold due to mutable dietary habits, consumption of fatty and cold food in abundance etc. In Unani System of Medicine, NAFLD has not been described as such, but it can be studied under Su’-i-Mizāj Kabid Bārid due to correlation of most of the symptoms. Its management mainly consists of elimination of morbid matter which is accumulated in the liver and correction of Su’-i-Mizāj Kabid Bārid by using drugs having opposite temperament (Ilaj bil zid).

scholarly journals Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease

2018 ◽  
Vol 24 (36) ◽  
pp. 4104-4118 ◽  
Author(s):  
Jorge-Luis Torres ◽  
Ignacio Novo-Veleiro ◽  
Laura Manzanedo ◽  
Lucía Alvela-Suárez ◽  
Ronald Macías ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Liver Disorders ◽  
Alcoholic Fatty Liver Disease

scholarly journals Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1714 ◽  
Author(s):  
Benoit Smeuninx ◽  
Ebru Boslem ◽  
Mark A. Febbraio
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Options ◽  
Critical Factor ◽  
Developed Countries ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Obesity is recognised as a risk factor for many types of cancers, in particular hepatocellular carcinoma (HCC). A critical factor in the development of HCC from non-alcoholic fatty liver disease (NAFLD) is the presence of non-alcoholic steatohepatitis (NASH). Therapies aimed at NASH to reduce the risk of HCC are sparse and largely unsuccessful. Lifestyle modifications such as diet and regular exercise have poor adherence. Moreover, current pharmacological treatments such as pioglitazone and vitamin E have limited effects on fibrosis, a key risk factor in HCC progression. As NAFLD is becoming more prevalent in developed countries due to rising rates of obesity, a need for directed treatment is imperative. Numerous novel therapies including PPAR agonists, anti-fibrotic therapies and agents targeting inflammation, oxidative stress and the gut-liver axis are currently in development, with the aim of targeting key processes in the progression of NASH and HCC. Here, we critically evaluate literature on the aetiology of NAFLD-related HCC, and explore the potential treatment options for NASH and HCC.

scholarly journals Biochemical changes in Non-alcoholic fatty liver disease (NAFLD): A study in Nepalese Population

2017 ◽  
Vol 2 (2) ◽  
pp. 15-20
Author(s):  
Pooja Maharjan ◽  
Puspa Raj Khanal ◽  
Narayan Prasad Parajuli ◽  
Govardhan Joshi ◽  
Hridaya Parajuli ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Biochemical Parameters ◽  
Developed Countries ◽  
Western World ◽  
Control Group ◽  
P Value ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common liver problem in the western world and is a clinicopathologic entity increasingly recognized as a major health burden in developed countries. Different laboratory tests are extremely useful in achieving a better understanding of diseases, and thereby, allow making decision for better management. The examination of different biochemical parameters usually provides excellent clues to the cause of the disease. The present study was conducted with the aim to assess the biochemical markers in Non alcoholic fatty liver disease (NAFLD) patients in Nepalese population.Methods: The biochemical parameters were investigated in 75 NAFLD patients, and 70 normal participants. The diagnosis of hepatic steatosis was established by abdominal ultrasound examination. All patients diagnosed as NAFLD were investigated for biochemical parameters and see the relationship between NAFLD and control was studied.Results: The findings of all biochemical parameters were raised in NAFLD patients in comparison with non-fatty liver control group and the differences were found to be statistically (P value less than 0.005) significant.Conclusions: NAFLD is associated with changes in biochemical parameters in cases of NAFLD. Its early detection will help in modifying the disease course, delaying complications and will also play a major role in preventive cardiology.Ann. Clin. Chem. Lab. Med. 2016:2(2);15-20

scholarly journals Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD)

2022 ◽  
Vol 8 (1) ◽  
Author(s):  
Aman Sharma
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Therapeutic Target ◽  
Fatty Liver Disease ◽  
Lipid Droplets ◽  
Alcoholic Fatty Liver ◽  
The World ◽  
Associated Proteins ◽  
Pharmacological Target ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is now the most common form of chronic liver disease in the world, and it’s linked to a slew of other risk factors including diabetes, obesity, dysbiosis and inflammatory bowel disease. More than 30 years ago, a patient was diagnosed with fatty liver with excessive fat accumulation in hepatocytes, a disorder known as hepatosteatosis. There will be no promising therapeutic medicines available from 1980 to 2021 which can reverse the fatty liver to normal liver state. In this review, we highlighted on lipid droplet associated protein which play a major role in accumulation of fat in liver cells and how these cellular pathway could be a promising therapeutic approach to treat the fatty liver disease. Main body Over the last few decades, Western countries follow a high-fat diet and change their lifestyle pattern due to certain metabolic disorders prevalence rate is very high all over the world. NAFLD is a major health issue and burden globally nowadays. Researchers are trying to find out the potential therapeutic target to combat the disease. The exact pathophysiology of the disease is still unclear. In the present decades. There is no Food and Drug Administration approved drugs are available to reverse the chronic condition of the disease. Based on literature survey, lipid droplets and their associated protein like perilipins play an eminent role in body fat regulation. In this review, we explain all types of perilipins such as perilipin1-5 (PLIN1-5) and their role in the pathogenesis of fatty liver which will be helpful to find the novel pharmacological target to treat the fatty liver. Conclusion In this review, majorly focussed on how fat is get deposited into hepatocytes follow the cellular signalling involved during lipid droplet biogenesis and leads to NAFLD. However, up to date still there mechanism of action is unclear. In this review, we hypothesized that lipid droplets associated proteins like perilipins could be better pharmacological target to reverse the chronic stage of fatty liver disease and how these lipid droplets associated proteins hide a clue to maintain the normal lipid homeostasis in the human body.

scholarly journals Non-alcoholic Fatty Liver Disease and Postoperative Hypothyroidism in Women: Clinical and Pathogenetic Parallels

2021 ◽  
Vol 17 (16) ◽  
pp. 40-45
Author(s):  
G.S. Dzhulay ◽  
◽  
S.V. Shchelochenkov ◽  
O.N. Guskova ◽  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Disorders ◽  
Fat Distribution ◽  
Atherogenic Dyslipidemia ◽  
Alcoholic Fatty Liver ◽  
Liver Disorders ◽  
Alcoholic Fatty Liver Disease

Objective – to establish the clinical and pathogenetic patterns of the formation and course of non-alcoholic fatty liver disease in women with postoperative hypothyroidism. Material and methods. In a single-stage study of the "case-control" type of 170 women (Me aged 50 years), anthropometric data, parameters of carbohydrate, lipid, and protein metabolism, liver function tests were studied in the presence and absence of postoperative hypothyroidism. Results. It was found that in 86.2% of women with postoperative hypothyroidism, non-alcoholic fatty liver disease develops mainly in the form of steatohepatosis without distinct functional liver disorders. Insulin resistance and atherogenic dyslipidemia are found in the vast majority of them, the degree of their severity is determined by the presence of excess body weight with android and intermediate types of fat distribution. The greatest diagnostic value in the aspect of the probability of developing non-alcoholic fatty liver disease and metabolic disorders have a body mass index of Ketle and the ratio of the waist to the circumference of the hips. For the detection of metabolic disorders, the most significant insulin resistance index HOMA-IR, HDL, VLDL, ApoB, ApoB/ApoA1 index. Conclusion. In women with postoperative hypothyroidism in 86.2% of cases non-alcoholic fatty liver disease develops mainly in the form of steatohepatosis, characterized by a oligosymptomatic course without distinct functional liver disorders, the development of insulin resistance and atherogenic dyslipidemia, the severity of which is determined by the body mass index and the type of fat distribution

Sign in / Sign up

Export Citation Format

Share Document